This announcement is a separate document:
未名医药：浙江天册（深圳）律师事务所关于山东未名生物医药股份有限公司2023年股票期权激励计划第一期行权条件成就及注销部分股票期权事项的法律意见书
Shandong Sinobioway Biomedicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on the fulfillment of the terms of reference of the first phase of the 2023 Stock Option Incentive Plan of Shandong Weiming Biomedical Co., Ltd. and the cancellation of some stock options
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated